Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.65) by 16.92 percent. This is a 14.89 percent decrease over losses of $(0.47) per share from the same period last year.
Credit Suisse Initiates Coverage On Big Lots with Underperform Rating, Announces Price Target of $15
Credit Suisse analyst Karen Short initiates coverage on Big Lots (NYSE:BIG) with a Underperform rating and announces Price Target of $15.
